Speaker

Nikolai Naryshkin

Chief Scientific Officer, Ribonaut Therapeutics

Nikolai Naryshkin, Chief Scientific Officer at Ribonaut Therapeutics, is speaking at 9th RNA-Targeted Drug Discovery & Development Summit (Boston, United States of America, 10–12 Nov 2026) in the session “Roundtable Discussion: Characterizing Functionally Meaningful RNA– Protein Complexes to Enable Productive Drug Discovery”.

Conferences: 1
Keynotes: 0
Upcoming: 1

Pharmacy & Pharmaceutical Sciences

Upcoming appearances

9th RNA-Targeted Drug Discovery & Development Summit
10–12 Nov 2026Boston, United States of America
- PanelRoundtable Discussion: Characterizing Functionally Meaningful RNA– Protein Complexes to Enable Productive Drug Discovery
- PanelPanel Discussion: Establishing RNA-Targeted Small Molecules as a Generalizable Drug ModalityWith Tom Chappie, Yann Foricher

More speakers at 9th RNA-Targeted Drug Discovery & Development Summit

Scott Barraza
Associate Director, Early Discovery Chemistry, PTC Therapeutics
Robert Batey
Professor & Associate Chair of Graduate Affairs, University of Colorado Boulder
Ann Boija
Chief Scientific Officer, Dewpoint Therapeutics
Andrea Casazza
Head of Cancer Biology, EPICS Therapeutics
Dalya Gartzman
Chief Executive Officer, Renasis Bio
Paraskevi Gkeka
Distinguished Scientist, Group Head CADD, Sanofi

See all 21 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Nikolai Naryshkin, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].